CVS Health (CVS) Reports In-Line Q3 EPS; Issues Light FY16 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Margin Pressures Could Weigh on CVS Health (CVS) Shares; Oppenheimer Cuts Price Target to $115
November 2, 2015 11:16 AM ESTOppenheimer maintained an Outperform rating on CVS Health (NYSE: CVS), and cut the price target to $115.00 (from $122.00), following the company's 3Q earnings results. CVS reported 3Q revenue of $38.6B vs. consensus $37.9B. Adj. EPS was $1.29, in line with consensus $1.29. Analyst Mohan Naidu believes that the margin outlook and lack of clarity on organic growth in... More
Leerink Partners Would Buy CVS Health (CVS) on Current Weakness
October 30, 2015 1:39 PM EDTLeerink Partners reiterated an Outperform rating and $125.00 price target on CVS Health (NYSE: CVS) following the company's 3Q earnings and conference call. Management highlighted that the core business continues to grow at a healthy rate. While 2016E EPS guidance is below consensus expectations, management reiterated that their longterm adjusted EPS growth... More
